ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,304.72
0.70%
US Tech 100
18,318.00
0.95%
다우존스 지수
39,069.59
0.01%
Bitcoin
68,953.49
-0.45%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Eiger BioPharmaceuticals Inc (EIGR)

  7. Eiger BioPharmaceuticals Inc (EIGR) 뉴스

EIGR

Eiger BioPharmaceuticals (EIGR)

Eiger BioPharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:EIGR
일자시간출처헤드라인심볼기업
2024/04/0200:12GlobeNewswire Inc.Eiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/03/1205:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/2506:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/1907:49PR Newswire (US)Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/0821:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/0422:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/0422:00PR Newswire (US)Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock SplitNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/12/1206:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/12/0420:01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/12/0206:02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/2420:01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1406:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1006:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1006:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1006:05PR Newswire (US)Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/0310:54Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/0310:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/10/3105:51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/10/2105:29Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/2905:54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/1306:17Dow Jones NewsEiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing TalksNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/1305:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/1305:05PR Newswire (US)Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis DeltaNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/0610:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/0610:35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/0605:05PR Newswire (US)Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1519:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1505:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1505:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1505:05PR Newswire (US)Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:EIGR

최근 히스토리

AMEX
ROKT
SPDR S&P Kensho Final Fr...
NEO
SBUX
Starbucks CDR Cad Hedged
NASDAQ
MSAIAX
Morgan Stanley Portfolio...
BIT
FLV051
Vontobel
BIT
S29783
Societe Generale Effekten
KOSPI
003280
흥아해운
BIT
GS0225
Goldman Sachs
BIT
UV8C7R
UniCredit Bank
COIN
HIDEOUSUST
Hideous
COIN
RVNBTC
Ravencoin
NASDAQ
AAZPWXX
Morgan Stanley Finance L...
LSE
82UB
Arran 2.bc56a
NASDAQ
CHYBAX
WTCCIF II Core High Yiel...
BITMOT
820044
Daimler Tf 2,125% Lg37 Eur
USOTC
CBCB
NASDAQ
IPKW
Invesco International Bu...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유